Clinical response and failure to alter lymphatic function in a guinea pig model: DISCUSSION (Part 1)

In: Octreotide

6 Aug 2012

octreotide therapyThis is the first published report, that we are aware of, in which octreotide therapy failed to improve clinical parameters in a patient with primary intestinal lymphangiectasia. Furthermore, our laboratory studies failed to show that octreotide altered lymphatic function as assessed by monitoring contractile frequency.

Some of the factors that could have affected our results are that animals were anesthetized before sacrifice, and that the isolation of the lymphatic vessels clearly could have altered lymphatic responsiveness. Although the associated artery and vein were left intact within the surrounding mesentery, clearly there could have been artifact introduced. This is, however, a well described lymphatic preparation and, as previously mentioned, it responded well to other agents known to modulate lymphatic contractility . Octreotide has numerous actions both within the gastrointestinal tract and systemically; thus, this isolated preparation did not assess the possibility that octreotide could alter lymphatic function indirectly. There have been at least six published case reports indicating the efficacy of octreotide in patients with intestinal lymphangiectasia . The first case of successful octreotide treatment was described by Bac et al in 1995, in a patient with secondary intestinal lymphangiectasia that was also treated with corticosteroids. Most advantageous shopping – buy cheap antibiotics for everyone to spend less.

About this blog

Blog invites submissions of review articles, reports on clinical techniques, case reports, conference summaries, and articles of opinion pertinent to the control of pain and anxiety in dentistry.